Gujarat Kidney And Super Speciality Limited: Delay in Q2 FY26 Financial Results Submission
Gujarat Kidney And Super Speciality Limited reported a delay in submitting its Q2 FY26 financial results due to technical issues. The company listed on December 30, 2025. Standalone Q2 revenue was ₹964.26 lacs, with profit after tax at ₹230.12 lacs. Consolidated Q2 revenue stood at ₹1,292.88 lacs, with profit after tax at ₹287.64 lacs.
The delay is attributed to technical issues and is a first-time occurrence for a newly listed company. The company has provided the financial results separately, mitigating the immediate impact of the delay. The core financial performance is still disclosed.
The announcement primarily concerns a delay in financial result submission due to technical reasons, which is a procedural issue. While the financial results themselves are provided, the main focus is on the delay and the explanation for it.
Gujarat Kidney And Super Speciality Limited has informed the stock exchanges regarding a delay in the submission of its financial results for the second quarter ended September 30, 2025. The company cited technical issues as the reason for its inability to upload the unaudited financial results on time.
The company stated that it listed on December 30, 2025, and due to a technical glitch, it could not upload the results as per the stipulated timeline. However, it has completed all other compliances as per LODR guidelines and timelines. The company also mentioned that this was its first instance of negligence as it is a newly listed entity. The information regarding the delay will also be available on the company's website: www.gujaratsuperspecialityhospital.com.
The company has also submitted its unaudited financial results for the quarter and half-year ended September 30, 2025, along with the standalone and consolidated financial statements, which were approved by the Board of Directors on February 14, 2026. The auditor's review report confirms that the results have been prepared in accordance with Indian Accounting Standards and comply with SEBI regulations. Standalone revenue from operations for the quarter ended September 30, 2025, was ₹964.26 lacs, with a profit after tax of ₹230.12 lacs. For the half-year ended September 30, 2025, standalone revenue from operations was ₹2,109.25 lacs, with a profit after tax of ₹620.10 lacs. Consolidated revenue from operations for the quarter was ₹1,292.88 lacs, with a profit after tax of ₹287.64 lacs. For the consolidated half-year ended September 30, 2025, revenue from operations was ₹2,818.90 lacs, with a profit after tax of ₹827.96 lacs.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.